Clinical trials: Metastatic Neoplasm
Non Small Cell Lung Cancer
Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy
To determine if ZD6474 a new investigational drug, is effective in treating Non Small Lung Cancer and if so, how it compares with another type of anti cancer therapy chemotherapy, Erlotinib
- Trial name
- NCT00364351
- Testing
- Vandetanib, Erlotinib
- Where
- 153 sites in United States, Argentina and 20 more
- Volunteers
- 1,574 people
- Sponsor
- Genzyme, a Sanofi Company
Esophageal Cancer, Gastroesophageal Junction Cancer
Sorafenib for Patients With Metastatic or Recurrent Esophageal and Gastroesophageal Junction Cancer
Sorafenib is a drug being studied for the treatment of cancer. Sorafenib has been shown to block certain proteins on the surface of some cancer cells called "growth factor receptors." Blocking these growth factor receptors can…
- Trial name
- NCT00917462
- Testing
- Sorafenib, administered orally, CT/MRI
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Soft Tissue Sarcoma
LTX-315 and Adoptive T-cell Therapy in Advanced Soft Tissue Sarcoma (ATLAS-IT-04)
ATLAS-IT-04 is a two part, single arm study designed to determine the safety and effectiveness of LTX-315 to induce T-cell infiltration prior to TIL expansion in patients with soft tissue sarcoma.
- Trial name
- NCT03725605
- Testing
- LTX-315 and TILs
- Where
- Denmark
- Volunteers
- 6 people
- Sponsor
- Lytix Biopharma AS
Cervical Cancer, Pancreatic Cancer
CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer
Background: The National Cancer Institute (NCI) Surgery Branch has developed an experimental therapy for treating patients with metastatic cancer that involves taking white blood cells from the patient, growing them in the…
- Conditions
- Cervical Cancer, Pancreatic Cancer, Ovarian Cancer, Mesothelioma
- Trial name
- NCT01583686
- Testing
- Fludarabine, Anti-mesothelin chimeric T cell receptor (CAR) transduced peripheral blood lymphocytes (PBL), Cyclophosphamide
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- National Cancer Institute (NCI)
Invasive Breast Cancer, Metastatic Breast Cancer
Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC
This research study is evaluating the safety and effectiveness of Sacituzumab Govitecan with or without Pembrolizumab in metastatic HR+/HER2- breast cancer.
- Conditions
- Invasive Breast Cancer, Metastatic Breast Cancer, HR-Positive Breast Cancer, HER2-negative Breast Cancer
- Trial name
- NCT04448886
- Testing
- Pembrolizumab, Sacituzumab Govitecan
- Where
- 8 sites in United States
- Volunteers
- 110 people
- Sponsor
- Ana C Garrido-Castro, MD
Metastatic Leiomyosarcoma
SARC018: A Study of Mocetinostat and Gemcitabine in Patients With Metastatic Leiomyosarcoma
This is an open-label, multi-center, Phase II trial studying the combination of mocetinostat and gemcitabine in patients who have previously demonstrated disease progression either while, or within six months after, receiving…
- Trial name
- NCT02303262
- Testing
- Mocetinostat, Gemcitabine
- Where
- 5 sites in United States
- Volunteers
- 20 people
- Sponsor
- Sarcoma Alliance for Research through Collaboration
Non-Small-Cell Lung Cancer
A Study for Non-Smoker Patients With Nonsquamous Non-Small Cell Lung Cancer
The purpose of this study is to compare the combination of erlotinib and pemetrexed versus either pemetrexed alone and erlotinib alone, in terms of progression-free survival (time until the objective worsening of the disease) in…
- Trial name
- NCT00550173
- Testing
- pemetrexed, erlotinib
- Where
- 29 sites in Brazil, China and 5 more
- Volunteers
- 247 people
- Sponsor
- Eli Lilly and Company
Metastatic Prostate Cancer
PRAGMA (Prostate Radio Ablation Guided by Magnetic Resonance Imaging Acquisition) in Metastatic Prostate Cancer
Patients with metastatic prostate cancer can undergo MRI-guided prostate Stereotactic body radiation therapy (SBRT) without significant adverse events, similar to what has been reported for patients with localized prostate…
- Trial name
- PRAGMA (NCT04220983)
- Testing
- MR-Guided Prostate SBRT
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Weill Medical College of Cornell University
Breast Neoplasms, Secondary
Pilot Imaging Study With 89Zr-Trastuzumab in HER2-positive Metastatic Breast Cancer Patients
Evaluation of the diagnostic potential of HER2 imaging using zirconium 89 labelled trastuzumab.
- Conditions
- Breast Neoplasms, Secondary, HER2 Positive Carcinoma of Breast
- Trial name
- IJBMNZrT003 (NCT01420146)
- Testing
- Zr89-trastuzumab
- Where
- Belgium
- Volunteers
- 20 people
- Sponsor
- Jules Bordet Institute
Metastatic Melanoma, Head Neck Cancer
A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
This is a phase 1b/2, open-label, multicenter trial designed to evaluate the safety, tolerability, biologic activity, and preliminary efficacy of intratumoral SD-101 injections in combination with intravenous pembrolizumab in…
- Trial name
- NCT02521870
- Testing
- SD-101(1), Pembrolizumab, SD-101(2)
- Where
- 47 sites in United States, Australia and 2 more
- Volunteers
- 241 people
- Sponsor
- Dynavax Technologies Corporation
Head and Neck Cancer
Bempegaldesleukin (NKTR-214) With Radiation and Anti-PD-1 Immunotherapy for Head and Neck Squamous Cell Carcinoma
This trial will evaluate safety and efficacy of the combination of anti-PD1, NKTR-214, and palliative radiation therapy in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
- Trial name
- NCT04936841
- Testing
- NKTR-214, anti-PD-1 therapy, Palliative Radiation
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Wisconsin, Madison
Breast Cancer, Cervical Cancer
T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-A*01 Positive
Background: The National Cancer Institute (NCI) Surgery Branch has developed an experimental therapy for treating patients with cancer that involves taking white blood cells from the patient, growing them in the laboratory in…
- Conditions
- Breast Cancer, Cervical Cancer, Renal Cancer, Melanoma
- Trial name
- NCT02153905
- Testing
- Aldesleukin, Fludarabine, Cyclophosphamide
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- National Cancer Institute (NCI)
Pancreatic Neoplasms, Pancreatic Cancer
Clinical Trial of High-dose Vitamin C for Advanced Pancreatic Cancer
This is a phase II study. It is designed to provide information about if high-dose ascorbate (vitamin C) increases survival for pancreatic cancer patients.
- Trial name
- PACMAN-II (NCT01515046)
- Testing
- Gemcitabine with escalating ascorbic acid
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Joseph J. Cullen
Melanoma
MAGE-A3 Antigen-Specific Cancer Immunotherapeutic in Patients With Progressive Metastatic Cutaneous Melanoma
This study is being done to evaluate the safety and the clinical activity of MAGE-A3 Antigen-Specific Cancer Immunotherapeutic in patients with unresectable and progressive metastatic cutaneous melanoma.
- Trial name
- NCT00706238
- Testing
- GSK Biologicals' Recombinant MAGE-A3 Antigen-Specific Cancer Immunotherapeutic (ASCI) GSK1203486A
- Where
- 6 sites in Argentina, Greece and 1 more
- Volunteers
- 5 people
- Sponsor
- GlaxoSmithKline
Metastatic HER2-Positive Breast Cancer
Gemcitabine, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer After Prior Trastuzumab/Pertuzumab, or Pertuzumab Based Therapy
The purpose of this study is to see if a combination of drugs can help to treat breast cancer. This is a Phase II study which will test whether this combination of drugs is effective and will provide further information on side…
- Trial name
- NCT02252887
- Testing
- Gemcitabine, Trastuzumab, Pertuzumab
- Where
- 5 sites in United States
- Volunteers
- 45 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Prostate Cancer
A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) in Non-metastatic Hormone Resistant Prostate Cancer
Enthuse M0 is a large phase III clinical trial studying the efficacy of ZD4054 (Zibotentan) in hormone resistant prostate cancer (HRPC).
- Trial name
- ENTHUSE M0 (NCT00626548)
- Testing
- ZD4054, Palcebo
- Where
- 322 sites in United States, Argentina and 37 more
- Volunteers
- 2,577 people
- Sponsor
- AstraZeneca
Cancer, Spinal Disease
Anderson Circulating Tumor Cell Burden (CTCB) Study
Phase 1 - Optimization Phase: Primary Objective: The primary objective of Phase 1 of this study is to determine the time point at which maximal Circulating Tumor Cell Burden (CTCB) occurs following standard vertebroplasty and…
- Conditions
- Cancer, Spinal Disease, Vertebral Compression Fractures
- Trial name
- NCT00819832
- Testing
- Kyphoplasty, Vertebroplasty, Cavity SpineWand
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- M.D. Anderson Cancer Center
Multiple Myeloma
A Multiple Myeloma Trial in Patients With Bone Metastases
The purpose of this trial is to study the safety of treating patients with multiple myeloma and at least one bone lesion with zoledronic acid 4mg intravenously (IV) every 3 - 4 weeks for 2 years.
- Trial name
- NCT00104104
- Testing
- zoledronic acid
- Where
- 68 sites in United States
- Volunteers
- 179 people
- Sponsor
- Novartis Pharmaceuticals
Melanoma, Malignant Melanoma
Phase II Study of Short-Term Cultured Anti-Tumor Autologous Lymphocytes After Lymphocyte-Depleting Chemotherapy in Metastatic Melanoma
Background: Most therapeutic therapies for metastatic melanoma have focused on the ability of T-cell lymphocytes to kill cells of tumors.
- Conditions
- Melanoma, Malignant Melanoma, Melanoma, Experimental, Experimental Melanomas
- Trial name
- NCT00513604
- Testing
- aldesleukin, therapeutic autologous lymphocytes, Cyclophosphamide
- Where
- United States
- Volunteers
- 158 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer
An Observational Follow-up Study of 1st-Line Treatment With Herceptin (Trastuzumab) in Patients With Metastatic Breast Cancer (Post-HERMINE)
This is an observational follow-up study on the efficacy of 1st-line treatment with Herceptin (trastuzumab) in patients with metastatic breast cancer 7 years after initiation of treatment.
- Trial name
- NCT01332981
- Where
- France
- Volunteers
- 220 people
- Sponsor
- Hoffmann-La Roche
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.